Relay Therapeutics (RLAY) and HLB's unit Elevar Therapeutics said Tuesday that the companies agreed to an up to $500 million exclusive global licensing deal for lirafugratinib.
Under the agreement, Relay Therapeutics will receive up to $75 million in upfront and regulatory milestone payments, $425 million in commercial milestone payments, plus double-digit royalties on global sales.
Additionally, Elevar Therapeutics is responsible for the further development and commercialization of lirafugratinib.
Lirafugratinib is currently under development as a potential treatment for bile duct cancer and other fibroblast growth factor receptor 2-altered solid tumors, according to the statement.
Shares of Relay Therapeutics were down 3.4% in recent trading.
Price: 4.51, Change: -0.16, Percent Change: -3.43
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.